Register
Login:
Share:
Email Facebook Twitter

Member Info for bigbob0228


Member Since: Mon, 7th Apr 2008

Number of Share Chat Posts (all time): 97
Number of Share Chat Posts (last 30 days): 8

Last Posted: Tue 16:55


Post Distribution over the last 30 days




Tue 16:55


Nearly 2.5 million shares bought between 16.35 and 16.52 after hours on the FTSE Aim market wonder if thats a omen for 2nd December.
Mon 07:53


GW Pharmaceuticals to Report Q4, Year-End 2014 Financial Results and Host Conference Call on 2 December, 2014

LONDON, Nov. 24, 2014 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will report on 2 December, 2014 its fourth quarter, year-end financial results for the period ending 30 September, 2014. GW will also host a conference call the same day at 8:00 a.m. EST/1:00 p.m. GMT.

Conference call information will be provided in the financial results press release. A replay of the call will also be available through the Company's website (www.gwpharm.com) shortly after the call.

About GW Pharmaceuticals plc

Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 27 countries outside the United States. Sativex is also in Phase 3 clinical development as a potential treatment of pain associated with advanced cancer. This Phase 3 program has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) and is intended to support the submission of a New Drug Application for Sativex in cancer pain with the FDA and in other markets around the world. GW has a deep pipeline of additional cannabinoid product candidates, including Epidiolex® in the treatment of childhood epilepsy, which has received Fast Track Designation from the FDA for Dravet syndrome as well as Orphan Drug Designations from the FDA in both the treatment of Dravet syndrome and Lennox-Gastaut syndrome. GW's product pipeline also includes compounds in Phase 1 and 2 clinical development for glioma, ulcerative colitis, type 2 diabetes, and schizophrenia. For further information, please visit www.gwpharm.com.

Enquiries:

GW Pharmaceuticals plc(Today) +44 20 3727 1000

Justin Gover, Chief Executive Officer(Thereafter) + 44 1980 557000

Stephen Schultz, VP Investor Relations (U.S.)917 280 2424 / 401 500 6570



FTI Consulting (Media Enquiries)

Ben Atwell / Simon Conway / John Dineen (UK)+ 44 20 3727 1000

Robert Stanislaro (U.S.)212 850 5657



Trout Group, LLC (U.S. investor relations)

Todd James / Chad Rubin646 378 2900

Source: GW Pharmaceuticals plc
19 Nov '14


Well here we go again good news and the price should go up to $90 bad and we could see $70 again

Good luck all
18 Nov '14


Yes I too have been waiting all day for Q4 results o well very pleased that I topped up at 307 hope to start taking profit again at 500pps lets hope we finish the year on a high and we all have a happy Christmas

GL all

Bob


Sign up for Live Prices
Top Recommended
Hot Chat Topics
Top recommended posters in the last 30 days
Share Price Spaceroptrade680 
Share Price SpacerBrotherhumble674 
Share Price Spaceronceatrader638 
Share Price SpacerK3VMC503 
Share Price Spacerrobbajob470 
Share Price Spacermatlot447 
Share Price SpacerBelcourtoi433 
Share Price SpacerGrumpyScouser408 




Member Login

Forgotten your password?
Email:

Password:


Don't have an account? Click here to Register Free!


Home  |  Contact Us  |  About Us  |  Careers  |  Advertise with Us  |  Sitemap  |  Terms & Conditions  |  Cookies  |  Privacy


Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.